The effect of sulindac on dermal responses to bradykinin in normal subjects given an angiotensin converting enzyme inhibitor.
The ability of sulindac to modify the weal response to four doses of intradermal bradykinin in subjects given enalapril was tested in a double-blind cross-over study in normal volunteers. The dose-dependent increase in skin thickness after bradykinin was significantly reduced by prior administration of sulindac. Certain of the actions and adverse effects of angiotensin converting enzyme inhibitors may be due to the interaction of prostaglandins and bradykinin.
Ferner
R E
RE
Wolfson Unit of Clinical Pharmacology, University of Newcastle upon Tyne.
Kamali
F
F
Rawlins
M D
MD
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D001920:Bradykinin / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004656:Enalapril / Q000494:pharmacology; D006801:Humans; D008297:Male; D011897:Random Allocation; D012039:Regional Blood Flow / Q000187:drug effects; D012867:Skin / Q000098:blood supply / Q000187:drug effects*; D013467:Sulindac / Q000494:pharmacology*
D000806:Angiotensin-Converting Enzyme Inhibitors; D013467:Sulindac; D004656:Enalapril; D001920:Bradykinin